Analyzing Catalyst Pharmaceuticals (NASDAQ:CPRX) & Aptorum Group (NASDAQ:APM)

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Aptorum Group (NASDAQ:APM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Analyst Recommendations

This is a summary of current recommendations for Catalyst Pharmaceuticals and Aptorum Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0	0	3	3	3.50
Aptorum Group	1	0	0	0	1.00

Catalyst Pharmaceuticals presently has a consensus price target of $34.00, indicating a potential upside of 29.47%. Given Catalyst Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Aptorum Group.

Profitability

This table compares Catalyst Pharmaceuticals and Aptorum Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	36.39%	36.47%	31.85%
Aptorum Group	N/A	N/A	N/A

Valuation and Earnings

This table compares Catalyst Pharmaceuticals and Aptorum Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99 million	5.44	$214.33 million	$1.69	15.54
Aptorum Group	$430,000.00	13.08	-$1.36 million	N/A	N/A

Catalyst Pharmaceuticals has higher revenue and earnings than Aptorum Group.

Volatility and Risk

Catalyst Pharmaceuticals has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Aptorum Group has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

Institutional & Insider Ownership

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Comparatively, 64.0% of Aptorum Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Catalyst Pharmaceuticals beats Aptorum Group on 11 of the 13 factors compared between the two stocks.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.